Immunicum AB (publ) announced the completion of patient recruitment for the ongoing, global Phase II MERECA (MEtastatic REnal Cell CArcinoma) clinical trial. The study's primary objective is to provide proof of concept for ilixadencel through the achievement of multiple endpoints indicative of meaningful clinical impact and safety assessed over an 18-month period. The final number of patients randomized in the trial is 88, meeting the requirements of the study design and validity of the protocol, which had targeted to enroll up to 90 patients. The MERECA study is an international, randomized, controlled and open Phase II clinical trial. The aim is to examine the safety, tumor-specific immune activation and potential for clinical efficacy of two intratumoral doses of ilixadencel before surgical removal of the tumor-affected kidney and subsequent treatment with the standard of care-drug, sunitinib. In the control arm, patients are treated with sunitinib only, post surgical removal of the tumor-affected kidney. The study is designed to provide data on the clinical benefit through survival rate at 18 months and median overall survival for all patients.